



RESEARCH COUNCIL

*Find contradictions. Validate hypotheses.
Trust your literature*

36,000,000

papers on PubMed alone.

30%

of a researcher's time lost to literature review.


1

confident answer from every AI tool you've tried.

What if the answer came from
4 agents that read everything —
and had to convince each other first?



GraphRAG + Multi-LLM Council



NEXT →



Research Council

GraphRAG + Multi-LLM

+ New Research

Q Search Papers

📖 Ingested Papers

📊 View Graph

📁 Graph: default ▼

Are there contradictions in BRCA1'...

New research

125%

— +

Reset



Research Council

Ask any biomedical research question. The council of 4 AI agents will deliberate over the knowledge graph, cross-review each other, and deliver a confidence-scored, cited answer.

CONTRADICTION

Are there contradictions in BRCA1's role in triple-negative breast cancer?

HYPOTHESIS

Has anyone tested repurposing metformin for glioblastoma?

REVIEW

Summarize recent evidence on GLP-1 agonists and neurodegeneration

Ask a research question... e.g. What is the role of BRCA1 in ovarian cancer?



Search Papers



Sources:

All Sources

arXiv

PubMed

Papers with Code

Graph Storage:

aistore

default

medical

New

Or upload PDF:

Upload PDF

BRCA

Search

20 papers found

Clinical Management in BRCA Carriers with Early Breast Cancer.

PUBMED

2025 *Cancer control : journal of the Moffitt Cancer Center*

Muñante, Bruno, Paz-Manrique, Roberto, Pinto, Joseph A +1 more

BackgroundBreast cancer remains a leading cause of cancer-related morbidity and mortality globally, with BRCA1/2 mutation carriers facing distinct challenges due to aggressive tumor biology and height...

DOI

BRCA Mutations and Fertility Preservation.

PUBMED

2023 *International journal of molecular sciences*

Dias Nunes, Joana, Demeestere, Isabelle, Devos, Melody

Hereditary cancers mostly affect the adolescent and young adult population (AYA) at reproductive age. Mutations in *BReast CAncer*

×


📁 medical

PubMed

PubMed

PubMed

PMID: 38203374



Are there contradictions in BRCA1's role in triple-negative breast cancer?



The analysis of BRCA1's role in triple-negative breast cancer (TNBC) reveals several apparent contradictions in the literature. While BRCA1 mutations are consistently associated with increased risk of developing TNBC and higher levels of genomic instability, paradoxical findings emerge regarding prognosis and treatment response. BRCA1-mutated TNBC tumors demonstrate increased DNA damage and genomic instability, yet some studies report better overall survival rates and higher response rates to platinum-based chemotherapy in BRCA1-mutated TNBC patients compared to non-mutated cases. These contradictions may be explained by tumor heterogeneity, the dual nature of genomic instability (promoting both aggressiveness and treatment sensitivity), potential immune response differences, and epigenetic modifications. However, the current evidence base is limited by methodological inconsistencies, including variable TNBC definitions, selection bias, small sample sizes, lack of standardization in BRCA1 mutation detection, and potential publication bias.

Confidence



65%

Answer

Council (4)

Evidence

Graph

METHODOLOGY NOTES

The analysis is limited by the absence of specific paper citations from the knowledge graph. Multiple methodological concerns were identified across the reviewed literature: (1) Variable definitions and classification criteria for TNBC across studies; (2) Selection bias in patient recruitment, particularly regarding age, family history, and prior cancer diagnosis; (3) Small sample sizes limiting statistical power; (4) Lack of standardization in BRCA1 mutation detection methods; (5) Potential publication bias favoring positive findings; (6) Insufficient control for confounding variables such as age, tumor stage, and treatment history; (7) Limited stratification by TNBC molecular subtypes (basal-like, mesenchymal-like); (8) Retrospective study designs limiting causal inference. Future research should employ larger, prospective studies with standardized methodologies, integrate genomic and transcriptomic data, stratify by TNBC subtypes, and use advanced statistical methods including machine learning and propensity score matching.

KEY FINDINGS

BRCA1 mutations are associated with increased risk of developing triple-negative breast cancer

BRCA1-mutated TNBC tumors exhibit higher levels of DNA damage and genomic instability compared to non-BRCA1-mutated TNBC

Paradoxically, some studies report better overall survival rates in BRCA1-mutated TNBC patients

BRCA1 mutations are associated with higher response rates to platinum-based chemotherapy in TNBC

BRCA1-mutated TNBC patients may have shorter response times to platinum-based chemotherapy

the analysis of BRCA1's role in triple-negative breast cancer (TNBC), reveals several apparent contradictions in the literature. While BRCA1 mutations are consistently associated with increased risk of developing TNBC and higher levels of genomic instability, paradoxical findings emerge regarding prognosis and treatment response. BRCA1-mutated TNBC tumors demonstrate increased DNA damage and genomic instability, yet some studies report better overall survival rates and higher response rates to platinum-based chemotherapy in BRCA1-mutated TNBC patients compared to non-mutated cases. These contradictions may be explained by tumor heterogeneity, the dual nature of genomic instability (promoting both aggressiveness and treatment sensitivity), potential immune response differences, and epigenetic modifications. However, the current evidence base is limited by methodological inconsistencies, including variable TNBC definitions, selection bias, small sample sizes, lack of standardization in BRCA1 mutation detection, and potential publication bias.

Confidence



65%

Answer

 Council (4)

 Evidence

 Graph



 Evidence Agent

llama-3.3-70b-versatile

To address the research query regarding potential contradictions in BRCA1's role in triple-negative breast cancer (TNBC), I will analyze the provided ...



 Skeptic Agent

llama-3.3-70b-versatile

As a critical reviewer, I will analyze the role of BRCA1 in triple-negative breast cancer (TNBC) and identify potential contradictions and methodologi...



 Connector Agent

llama-3.1-8b-instant

Based on the retrieved context, I'll analyze the potential contradictions in BRCA1's role in triple-negative breast cancer.



 Methodology Agent

llama-3.1-8b-instant

As a researcher evaluating the methodology of the study, I will assess the appropriateness of the experimental design, controls, statistical methods, ...

search

ons in BRCA1...

some studies report better overall survival rates and higher response rates to platinum-based chemotherapy in BRCA1-mutated TNBC patients compared to non-mutated cases. These contradictions may be explained by tumor heterogeneity, the dual nature of genomic instability (promoting both aggressiveness and treatment sensitivity), potential immune response differences, and epigenetic modifications. However, the current evidence base is limited by methodological inconsistencies, including variable TNBC definitions, selection bias, small sample sizes, lack of standardization in BRCA1 mutation detection, and potential publication bias.

Confidence 65%

Answer

Council (4)

Evidence

Graph

KEY FINDINGS

BRCA1 mutations are associated with increased risk of developing triple-negative breast cancer

BRCA1-mutated TNBC tumors exhibit higher levels of DNA damage and genomic instability compared to non-BRCA1-mutated TNBC

Paradoxically, some studies report better overall survival rates in BRCA1-mutated TNBC patients

BRCA1 mutations are associated with higher response rates to platinum-based chemotherapy in TNBC

BRCA1-mutated TNBC patients may have shorter progression-free survival despite better initial treatment response

TNBC heterogeneity may explain contradictory findings, with BRCA1 mutations associated with distinct molecular subtypes

CONTRADICTIONS FOUND

BRCA1 mutations associated with both increased tumor aggressiveness (higher genomic instability) and better prognosis (improved overall survival)

Higher treatment response rates to platinum-based chemotherapy but shorter progression-free survival in BRCA1-mutated TNBC

Conflicting reports on BRCA1 expression levels in TNBC, with some studies showing decreased expression and others showing increased expression

Variable associations between BRCA1 mutations and TNBC across different studies, with some reporting significant associations and others finding no significant link

3,118 tokens used • Agent agreement: 80%

Ask a research question... e.g. What is the role of BRCA1 in ovarian cancer?



Thank You